ELDN — ELEDON PHARMACEUTICALS INC (Healthcare >> Biotechnology)
ELDN FAQ
What is ELDN's ROE?
ELEDON PHARMACEUTICALS INC reports a Return on Equity (ROE) of -77.79%.
What is ELDN's dividend yield?
ELEDON PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is ELDN's Deepscope Quality Score?
Deepscope rates ELDN's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ELDN?
Deepscope's AI Timing Score for ELDN is 71 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ELDN belong to?
ELEDON PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.49
Price
-0.04
(-1.13%)
Day Change
|
|
|---|
ELDN, the overall quality is not good ( Quality = 8) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.49 |
| PBV / Sector |
2.71 / 4.48
|
| Earning Per Share | -1.00 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
4.23 M
GREAT
|
| Average 1W Daily Value |
3.19 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:23 |
| Symbol | ELDN |
| Name | ELEDON PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 77.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 272.47 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 19800 MacArthur Boulevard, Irvine, CA, United States, 92612
Phone: 949 238 8090
Website: https://eledon.com
Sector: Healthcare >> Biotechnology
Description: Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google